DE19949575A1 - Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders - Google Patents
Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disordersInfo
- Publication number
- DE19949575A1 DE19949575A1 DE1999149575 DE19949575A DE19949575A1 DE 19949575 A1 DE19949575 A1 DE 19949575A1 DE 1999149575 DE1999149575 DE 1999149575 DE 19949575 A DE19949575 A DE 19949575A DE 19949575 A1 DE19949575 A1 DE 19949575A1
- Authority
- DE
- Germany
- Prior art keywords
- fluoride
- fluorides
- combination
- flavonoids
- caries
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 41
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 40
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 40
- 208000002925 dental caries Diseases 0.000 title claims abstract description 25
- 235000015218 chewing gum Nutrition 0.000 title claims abstract description 15
- 229940112822 chewing gum Drugs 0.000 title claims abstract description 14
- 239000000606 toothpaste Substances 0.000 title claims abstract description 11
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 title claims description 27
- 238000011282 treatment Methods 0.000 title abstract description 9
- 208000018035 Dental disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 150000002222 fluorine compounds Chemical class 0.000 claims abstract description 27
- 235000009508 confectionery Nutrition 0.000 claims abstract description 11
- 239000002324 mouth wash Substances 0.000 claims abstract description 8
- 229940051866 mouthwash Drugs 0.000 claims abstract description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 44
- 238000011321 prophylaxis Methods 0.000 claims description 14
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical class [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 14
- 235000010323 ascorbic acid Nutrition 0.000 claims description 13
- 239000011668 ascorbic acid Substances 0.000 claims description 13
- 229960005070 ascorbic acid Drugs 0.000 claims description 13
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical class F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- -1 amine fluorides Chemical class 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 235000013024 sodium fluoride Nutrition 0.000 claims description 7
- 239000011775 sodium fluoride Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000001055 chewing effect Effects 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 6
- 239000006187 pill Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 14
- 229960001245 olaflur Drugs 0.000 description 11
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 210000003298 dental enamel Anatomy 0.000 description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229960004555 rutoside Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 201000001245 periodontitis Diseases 0.000 description 5
- 238000004334 fluoridation Methods 0.000 description 4
- 235000020095 red wine Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000001013 cariogenic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- MBHXKZDTQCSVPM-BDAFLREQSA-N monoxerutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 MBHXKZDTQCSVPM-BDAFLREQSA-N 0.000 description 3
- 229960003443 monoxerutin Drugs 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960003232 troxerutin Drugs 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 102000008097 Aryl sulfotransferase Human genes 0.000 description 2
- 108060000550 Aryl sulfotransferase Proteins 0.000 description 2
- 206010007191 Capillary fragility Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940085398 ascorbic acid 50 mg Drugs 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000004042 dental fluorosis Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 229910004261 CaF 2 Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000219051 Fagopyrum Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010016818 Fluorosis Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010048886 Onychoclasis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229910008449 SnF 2 Inorganic materials 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003487 anti-permeability effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- 150000001530 aurones Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical class O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003306 rutin derivatives Chemical class 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/064—Chewing gum characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/126—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
Description
Die Erfindung betrifft eine neue Wirkstoffkombination von biologisch hochwirksamen Fluoriden (Aminfluoride (AmF) und/oder Zinkfluoride (SnF)) in Kombination mit Flavonoiden zur Karies und Zahnprophylaxe und Therapie von Zahnerkrankungen wie z. B. Parodontose. Verabreichbar ist die neue Wirkstoffkombination beispielsweise in der Applikationsform als Kaugummi, Kaudragee, Bonbon, Zahnpasta, Mundspülung oder in beliebig anderer Darreichungsform mit oder ohne Retardfunktion in der Mundhöhle. The invention relates to a new combination of active ingredients of biologically highly effective Fluorides (amine fluoride (AmF) and / or zinc fluoride (SnF)) in combination with Flavonoids for tooth decay and dental prophylaxis and therapy of dental diseases such as B. Periodontal disease. The new combination of active ingredients can be administered, for example, in Application form as chewing gum, chewing gum, candy, toothpaste, mouthwash or in any other dosage form with or without sustained release function in the oral cavity.
Zahnärztliche Leistungen machen bei der GKV (Stand 1996) ca. 10% der Ausgaben aus. 50-60% der Patienten bekommen bei ihrem Zahnarztbesuch ein oder zweiflächige Zahnfüllungen, aufgrund von Karies (in den neuen Bundesländern ist der Anteil höher). Karies hat in der Bevölkerung seit Jahren eine gleichbleibend hohe Prävalenz. Zahnkaries tritt in jeder Altersstufe auf, ist aber ein besonderes Problem für das anfällige kindliche und jugendliche Gebiß. Kariesbefall ist im frühen, hier noch prinzipiell reversiblen, Stadium für den Zahnarzt mit bloßem Auge nicht zu erkennen, da der kariöse Prozeß an der Suboberfläche beginnt. Im Extremfall kann die Läsion bis zum Erreichen des Dentins unsichtbar bleiben. Ziel muß es deshalb sein, frühzeitig wirkungsvolle Prophylaxemaßnahmen einzusetzen.Dental services account for approx. 10% of expenditure at the GKV (status 1996). 50-60% of patients receive one or two surfaces when they visit the dentist Tooth fillings due to tooth decay (the proportion is higher in the new federal states). Caries has had a consistently high prevalence in the population for years. Dental caries occurs at any age, but is a particular problem for the vulnerable child and youthful teeth. Caries infestation is in the early, here still reversible stage for the dentist cannot be seen with the naked eye because of the carious process on the sub-surface begins. In extreme cases, the lesion can remain invisible until it reaches the dentine. The aim must therefore be to use effective prophylactic measures at an early stage.
Ein weiteres, wichtiges und kostenintensives Problem, sind Erkrankungen der Mundschleimhaut, insbesondere Parodontose (Ursache für mehr als 30% aller Zahnarztbesuche). Betroffen von der Parodontose sind hauptsächlich ältere Patienten. Another important and costly problem are diseases of the Oral mucosa, especially periodontitis (cause of more than 30% of all Visits to the dentist). Periodontal disease mainly affects older patients.
Fluor (F: 19,00) gehört zur 7. Hauptgruppe des Periodensystems. Fluor findet sich in der Natur in Form verschiedener Fluoride. Fluoride sind wirksame Enzymgifte und beeinflussen besonders Phosphatasen. Fluoride werden aus dem Magen-Darm-Trakt schnell resorbiert. Die tägliche Aufnahme von Fluor in Form von Fluoriden sollte 1-2 mg nicht überschreiten.Fluorine (F: 19.00) belongs to the 7th main group of the periodic table. Fluorine is found in the Nature in the form of various fluorides. Fluorides are effective enzyme poisons and affect especially phosphatases. Fluorides are quickly absorbed from the gastrointestinal tract. The daily intake of fluorine in the form of fluorides should not exceed 1-2 mg.
0,25 g wirken beim Menschen toxisch, 4-5 g gelten als tödliche Dosis. Aus bisherigen Erkenntnissen weiß man, daß Fluoride bei richtiger Anwendung (und in der richtigen chem. Zusammensetzung) eine optimale Kariesprophylaxe bieten können. Einige haben die Potenz, beginnende Karies zu stoppen und den Zahnschmelz zu remineralisieren. Zusätzlich können bestimmte topisch lokal wirksame Fluoridkombinationen die Ausheilung einer Parodontose fördern bzw. deren Entstehung verhindern. In Kombination mit Glucose/Fructose- Verbindungen (insbesondere bei Süßwaren aller Art) wird das kariogene Potential der Zuckerverbindungen vermindert.0.25 g is toxic to humans, 4-5 g are considered a lethal dose. From previous ones Knowledge is known that fluoride when used correctly (and in the correct chem. Composition) can offer optimal caries prophylaxis. Some have the potency to stop caries starting and to re-mineralize the tooth enamel. In addition, you can certain topically locally active fluoride combinations heal periodontitis promote or prevent their emergence. In combination with glucose / fructose Connections (especially in confectionery of all kinds) will the cariogenic potential of Sugar compounds decreased.
Bislang gibt es keine optimale Applikationsform von Fluoriden, die die systemische mit der topischen Anwendung kombiniert und eine ausreichende Einwirkzeit garantiert. Insbesondere kann mit herkömmlichen Applikationsformen von Fluoriden keine Retardwirkung erzielt werden. So far, there is no optimal application form of fluorides that matches the systemic with the combined topical application and a sufficient exposure time guaranteed. In particular cannot achieve a sustained release effect with conventional application forms of fluorides become.
Flavonoide sind in Pflanzen weit verbreitete Farbstoffe. Es handelt sich um um Glykoside von Flavanonen, Flavonen, Flavonolen, Auronen, Isoflavonen und Rotenoiden. Flavonoide können sich in tierischen Membranen einlagern und nach oraler Applikation im vaskulären Endothel akkumulieren. Flavonoide erhöhen die Permeabilität der Körpergefäße und verringern die Kapillarbrüchigkeit. Diese Wirkungen werden besonders dem Rutin, Hesperidin und Naringin zugeschrieben. Ihnen wurde schon frühzeitig eine Ödem-präventive Wirkung im Rahmen der Therapie chronisch venöser Insuffizienzen im Beinbereich zugesprochen. Flavonoide zeigten im Tiermodell schmerzlindernde und fiebersenkende Wirkung, die durch eine Cyclooxygenase- und Lipidoxygenase-hemmende Wirkung begründet sein sollen. Die mildernde Wirkung von Flavonoiden auf allergischer Krankheitsbilder wird auf die Inhibition einer ATPase in der Membran der Mastzellgranula (Stabilisierung der Mastzellmembran) zurückgeführt. Flavonoide bilden starke Komplexe mit zweiwertigen Schwermetallionen (Fe2+, Cu2+, Zn2+) und können leicht oxidiert werden. Diese Eigenschaften machen diese Verbindungen zu hochwirksamen Radikalfängern und Antoxidantien. Flavonoide unterstützen synergistisch die Ascorbinsäurewirkung (z. B. Ausbildung mesenchymalen Gewebes).Flavonoids are widely used dyes in plants. These are glycosides of flavanones, flavones, flavonols, aurones, isoflavones and redoids. Flavonoids can accumulate in animal membranes and accumulate in the vascular endothelium after oral administration. Flavonoids increase the permeability of the body vessels and reduce the capillary fragility. These effects are particularly attributed to rutin, hesperidin and naringin. They were recognized early on to have an edema-preventive effect as part of the therapy of chronic venous insufficiency in the leg area. In the animal model, flavonoids showed pain-relieving and antipyretic effects, which are said to be due to a cyclooxygenase and lipidoxygenase-inhibiting effect. The mitigating effect of flavonoids on allergic diseases is attributed to the inhibition of an ATPase in the membrane of the mast cell granules (stabilization of the mast cell membrane). Flavonoids form strong complexes with divalent heavy metal ions (Fe 2+ , Cu 2+ , Zn 2+ ) and can be easily oxidized. These properties make these compounds highly effective radical scavengers and antioxidants. Flavonoids synergistically support the ascorbic acid effect (e.g. formation of mesenchymal tissue).
Flavonoide sind im Rotwein in hoher Konzentration enthalten. Rotwein enthält z. T. mehr als 1 g/l (vor allem Flavonoide wie Catechine und Anthocyane), während Weißwein gewöhnlich nicht mehr als 250 mg/l aufweist. Ein Grund für die bei mediterraner Bevölkerung seltener vorkommenden ischämischen Krankheitsbilder wie koronare Herzkrankheit und cerebrale Schlaganfälle stehen im Zusammenhang mit den im höheren Ausmaß mit der Nahrung konsumierten Flavonoide. Flavonoids are present in high concentrations in red wine. Red wine contains e.g. T. more than 1 g / l (especially flavonoids like catechins and anthocyanins), while white wine usually does not exceed 250 mg / l. A reason for that rare among the Mediterranean population occurring ischemic clinical pictures such as coronary heart disease and cerebral Strokes are related to those to a greater extent with food consumed flavonoids.
Die meisten Zahnpasten enthalten Fluoride. Häufig werden hierfür Dinatriumfluorophosphat (NaO)2PO(F) verwendet. Das Hauptproblem dieser Applikationsform ist die zu geringe Wirkzeit für Fluoride. Studien haben gezeigt, das eine optimale Kariesprophylaxe mit Fluoriden in niedriger Konzentration und mit ausreichender Wirkdauer zu erzielen ist (deshalb mind. 3 min. putzen erforderlich). Laut Statistik beträgt die durchschnittliche Zahnputzdauer allerdings nur 20 sec. Gängige Fluoridverbindungen können ihre Wirkung nicht optimal entfalten und besitzen keine Langzeitwirkung.Most toothpastes contain fluoride. Disodium fluorophosphate (NaO) 2 PO (F) is often used for this. The main problem with this form of application is that the action time for fluorides is too short. Studies have shown that optimal caries prophylaxis can be achieved with fluorides in low concentrations and with a sufficient duration of action (therefore cleaning at least 3 minutes required). According to statistics, however, the average tooth brushing time is only 20 seconds. Common fluoride compounds cannot develop their effects optimally and have no long-term effect.
Sind aufgrund der geringen Wirkdauer uneffektiv bis unwirksam.Are ineffective to ineffective due to the short duration of action.
Ein weiteres Problem stellt ihr Alkoholgehalt (Ethanol) dar. Die Gefahr eines Mißbrauchs ist hier gegeben. Aufgrund der Möglichkeit des Verschluckens und des Alkoholgehalts für Kinder ungeeignet. Another problem is their alcohol content (ethanol). There is a risk of abuse given here. Due to the possibility of ingestion and the alcohol content for Unsuitable for children.
Wirken praktisch nur systemisch. Auch Lutschtabletten bzw. Kaudragees sind als ungeeignet für eine effektive lokale Kariesprophylaxe anzusehen, da hier nur in der Mundhöhle und an der lingualen Seite der Zähne eine ausreichende Fluoridkonzentration erreicht wird. Die buccalen Approximalflächen der Zähne werden hierbei ausgespart, ebenso die Zahnzwischenräume und die buccalen Speicheldrüsen (Xerostomie).Actually only act systemically. Lozenges or chewable tablets are also unsuitable for an effective local caries prophylaxis, because here only in the oral cavity and on A sufficient fluoride concentration is achieved on the lingual side of the teeth. The The buccal approximal surfaces of the teeth are left out, as are the Interdental spaces and the buccal salivary glands (xerostomia).
Ein weiteres Problem dieser Darreichungsform ist die Fluoridkonzentration. Studien haben gezeigt, daß die optimale lokale Kariesprophylaxe nur mit Fluoriden in niedriger Konzentration zu erzielen ist. Bei Tabletten ist die Konzentration zu hoch. Bei Kindern besteht potentiell die Gefahr einer akuten Vergiftung, bzw. einer chronischen Überdosierung (Fluorose; erkennbar an gefleckten Zähnen (mottled teeth) und brüchigen Nägeln). Die tägliche Aufnahme von Fluor in Form von Fluoriden sollte 1-2 mg nicht überschreiten.Another problem with this dosage form is the fluoride concentration. Have studies shown that the optimal local caries prophylaxis only with fluorides in lower To achieve concentration. The concentration is too high for tablets. With children there is a potential risk of acute poisoning or chronic overdose (Fluorosis; recognizable by mottled teeth and brittle nails). The daily intake of fluorine in the form of fluorides should not exceed 1-2 mg.
Die Bioverfügbarkeit von Fluoriden wird durch gleichzeitige Nahrungsaufnahme (CaF2- Formation mit geringerer Resorption) reduziert. Fluoride sollten am besten zwischen den Mahlzeiten genommen werden. Gerade bei Kleinkindern, bei denen die Abstände zwischen den Nahrungsaufnahmen gering sind, ist eine exakte Dosierung kaum möglich.The bioavailability of fluorides is reduced by simultaneous food intake (CaF 2 formation with less absorption). It is best to take fluoride between meals. Exact dosing is hardly possible, especially for small children, where the intervals between food intake are small.
Bei älteren Kindern und Erwachsenen führte eine systemische Fluorid-Gabe zwar zur erhöhten
Adsorptionsrate, ohne die Konzentration im Zahnbereich nennenswert zu beeinflussen. Lokale
Fluorid-Gabe sollte daher bei der Karies- und Parodontoseprophylaxe im Vordergrund stehen.
Beispielmedikamente: "Luride" (USA) entsprechend 1 mg Fluorid aus 2,2 mg NaF
(1 OP mit 120 Tab).
"Fluoretten" Gehalt je Tablette 0,00055 g Natriumfluorid = 0,00025 g
Fluor.
In older children and adults, systemic administration of fluoride led to an increased adsorption rate without significantly influencing the concentration in the tooth area. Local fluoride administration should therefore be the focus of caries and periodontal prophylaxis.
Example drugs: "Luride" (USA) corresponding to 1 mg fluoride from 2.2 mg NaF (1 OP with 120 tabs).
"Fluorettes" content per tablet 0.00055 g sodium fluoride = 0.00025 g fluorine.
In der Schweiz seit 1983 mit höherer Dosierung (0,025% statt bislang 0,009% Fluorid) erhältlich.In Switzerland since 1983 with higher doses (0.025% instead of 0.009% fluoride) available.
In Deutschland seit kurzem in Kombination mit Jodid erhältlich.Recently available in Germany in combination with iodide.
Sehr niedriger durchschnittlicher natürlicher Fluorgehalt im Trinkwasser (z. B. Süddeutschland 0,129 mg/l). Bislang ist aufgrund der Gesetzeslage keine flächendeckende Fluoridierung vorgesehen. Trinkwasserfluoridierung wird ansonsten mit Alkalifluoriden durchgeführt.Very low average natural fluorine content in drinking water (e.g. Southern Germany 0.129 mg / l). So far, due to the legal situation, it is not nationwide Fluoridation provided. Drinking water fluoridation is otherwise done with alkali fluorides carried out.
Wird in den v. a. in den USA durchgeführt. Gilt aber als ineffektiv und kostenintensiv. Die topische Behandlung in Form einer Pinselung mit 2%iger Natriumfluoridlösung wird nur 1-2 mal/a durchgeführt (fehlende Kontinuität). Die hierbei verwendeten Fluorid-Dosen sind für eine lokale Behandlung zu hoch, verschluckte Mengen können signifikant sein. Is in the v. a. carried out in the USA. But is considered ineffective and costly. The topical treatment in the form of a brush with 2% sodium fluoride solution is only 1-2 times / a carried out (lack of continuity). The fluoride doses used here are for local treatment too high, swallowed amounts can be significant.
Flavonoide werden bislang lediglich in Gel-Form oral zur Prophylaxe der Parodontose angewendet. Eine synergistische Kombinationsanwendung von Flavonoiden und Fluoriden ist nicht bekannt. Dies gilt insbesondere im zusätzlichen Verbund mit Ascorbinsäure (Vitamin C). Flavonoide werden klinisch bei der Therapie chronisch venöser Insuffizienzen im Beinbereich oral verabreicht.So far, flavonoids have only been used orally in gel form for the prophylaxis of periodontitis applied. A synergistic combination application of flavonoids and fluorides is not known. This is especially true in the additional combination with ascorbic acid (vitamin C). Flavonoids are used clinically in the treatment of chronic venous insufficiency in the Leg area administered orally.
Flavonoide sind typischerweise in hoher Konzentration im Rotwein enthalten (ca. 1 g/l) und werden mit der Nahrung konsumiert. Flavonoids are typically contained in high concentrations in red wine (approx. 1 g / l) and are consumed with food.
- - Fluoride katalysieren die Remineralisation- Fluorides catalyze remineralization
- - Fluoride vermindern die Rate der Demineralisation- Fluorides reduce the rate of demineralization
- - Härtung erweichten Schmelzes und die histologische Reparation ist experimentell am Menschen nachgewiesen- Hardening softened enamel and the histological repair is experimentally proven in humans
-
- Plaquebeeinflussung:
- - Wachstumshemmung von Microorganismen
- - Bremsung der Glykolyse (bes AmF)
- - Inhibition of growth of microorganisms
- - braking of glycolysis (especially AmF)
- - NaP gibt komplex geb. F in relativ geringen Konz. als Fluorid ab.- NaP gives complex born F in relatively low concentrations as fluoride.
- - F-Gabe (z. B. im Trinkwasser) führt bei alten Menschen zu signifikant geringerer Anzahl an Frakturen im Oberschenkelhalsbereich.- F-administration (e.g. in drinking water) leads to significant in older people lower number of fractures in the femoral neck area.
- - Bei Osteoporose-Patienten führt Ca-Gabe mit kontinuierlicher F-Gabe zu signifikant geringeren Frakturraten (reg) (20 mg/d)- In osteoporosis patients, Ca administration leads to continuous F administration significantly lower fracture rates (reg) (20 mg / d)
- - APF Prinzip: niedriger pH steigert Fluoridaufnahme des Schmelzes- APF principle: low pH increases fluoride absorption in the enamel
- - Ausscheidungsrate über die Niere 50-80%- Kidney excretion rate 50-80%
- - führen zu einer höheren F-Konzentration auf der Schmelzoberfläche und bauen ein F-Depot auf der Schmelzoberfläche auf- lead to a higher F concentration on the enamel surface and build an F-depot on the enamel surface
- - haben im Vergleich zu MFP eine 4× größere Fluoretention (Zahnpasta)- have 4 × greater fluoride retention (toothpaste) than MFP
- - AmF/SnF2 hemmen das Plaquewachstum synergistisch- AmF / SnF 2 synergistically inhibit plaque growth
- - längere Verweildauer in der Plaque (gegenüber NaF 4× länger), Plaquophilie- longer stay in the plaque (compared to NaF 4 × longer), plaquophilia
- - stabilere Fluoridanreicherung- more stable fluoride enrichment
- - Tensidcharakter, AmF lagert sich als kationaktive Substanz an die bakterielle Zellmembran an- Surfactant character, AmF attaches itself to the bacterial as a cation-active substance Cell membrane
- - wirkt bakterizid (Keimreduktion <95%)- has a bactericidal effect (germ reduction <95%)
- - antiglykolytische Wirkung- antiglycolytic effect
- - saurer pH fördert F-reiche Oberflächenschicht am Zahnschmelz- Acidic pH promotes F-rich surface layer on the tooth enamel
- - 3-6 h wirksam, signifikant langsamere orale Fluorclearance- 3-6 h effective, significantly slower oral fluorine clearance
- - reduziert die Säurelöslichkeit der Schmelzoberfläche- reduces the acid solubility of the enamel surface
- - Bildung eines bakteriophoben, die Plaquebildung hemmenden Schutzfilmes- Formation of a bacteriophobic protective film that inhibits plaque formation
Die Sonderstellung der Amin/Zink-fluoride als biologisch besonders wirksame Stoffgruppe zur Prophylaxe und Therapie von Zahnerkrankungen, insbesondere Zahnkaries ist durch zahlreiche Studien und den entsprechenden Veröffentlichungen belegt (H. Schmidt, Chemie und Oberflächenwirkungen der Aminfluoride, Dtsch. Zahnärztl. Z. 38, 1983, Sonderheft 1; H.-J. Gülzow, Wirksamkeit von Aminfluoriden, Dtsch. Zahnärztl. Z. 38, 1983, Sonderheft 1; F. Lutz, Mechanismus der protrahierten Aminfluoridwirkung, Dtsch. Zahnärztl. Z. 38, 1983, Sonderheft 1; Schmid R. and Mühlemann H. R.: Effects of organic and inorganic fluoride dentitrices on rat caries incidence. J. Dent. Res. 62 Abstr. 75, 506 (1983)). The special position of amine / zinc fluoride as a biologically particularly effective group of substances for the prophylaxis and therapy of dental diseases, especially dental caries is through numerous studies and the corresponding publications documented (H. Schmidt, chemistry and surface effects of amine fluorides, Dtsch. Dentist Z. 38, 1983, special issue 1; H.-J. Gülzow, Effectiveness of Amine Fluorides, Dtsch. Dentist Z. 38, 1983, special issue 1; F. Lutz, Mechanism of the Protected Amine Fluoride Effect, Dtsch. Dentist Z. 38, 1983, Special issue 1; Schmid R. and Mühlemann H. R .: Effects of organic and inorganic fluoride dentitrices on rat caries incidence. J. Dent. Res. 62 Abstr. 75, 506 (1983)).
Flavon-Derivate mindern die erhöhte Durchlässigkeit der Kapillaren und normalisieren so die Permeabilität. Die Gefahr der Kapillarbrüchigkeit wird hiermit vermindert. In Pflanzen spielen phenolische Flavonderivate z. T. die Rolle von Redoxkatalysatoren. In der Darmwand hemmen die Flavonoide des Rotweins wirksam das Enzym Phenolsulfotransferase (PST). Dieses Enzym inaktiviert ein breites Spektrum von Phenolen durch Konjugation mit Sulfat. Die Flavonoide könnten so dafür sorgen, daß nicht sulfatierte Phenole resorbiert werden. Als Therapeutikum finden beispielsweise Rutoside (= Rutin) Verwendung. Aufgrund ihrer oben beschriebenen Wirkungsweise wurden Flavonoide früher als Antipermeabilitätsfaktor oder als Vitamin P bezeichnet. Bekannt war zunächst, das Vitamin P synergistisch die Ascorbinsäure (Vitamin C) unterstützt. Vitamin C Mangel führt zu Erkrankungen des Bindegewebes (fehlende Ausbildung mesenchymalen Gewebes) wie Skorbut. Für die Behandlung der Parodontose, ebenfalls eine Erkrankung des Bindegewebes des Zahnfleisches, wirken daher Flavonoide im Verbund mit Ascorbinsäure synergistisch. Gewonnen werden Rutoside u. a. aus Buchweizen (Fagopyrum-Arten, enthalten 1-4% Rutosid) oder aus Blütenknospen der japanischen Pflanze Sophora japonica (enthalten ca. 15% Rutosid) oder werden mit synthetisiert.Flavon derivatives reduce the increased permeability of the capillaries and thus normalize them Permeability. This reduces the risk of capillary fragility. In plants play phenolic flavone derivatives e.g. T. the role of redox catalysts. In the intestinal wall The red wine flavonoids effectively inhibit the enzyme phenolsulfotransferase (PST). This enzyme inactivates a wide range of phenols by conjugation with sulfate. The flavonoids could thus ensure that non-sulfated phenols are absorbed. As Therapeutic agents are used, for example, rutosides (= rutin). Because of her above Mode of action described flavonoids were previously used as an anti-permeability factor or as Called vitamin P. At first it was known that vitamin P synergistically ascorbic acid (Vitamin C) supports. Vitamin C deficiency leads to connective tissue diseases (lack of formation of mesenchymal tissue) such as scurvy. For the treatment of Periodontitis, also a disease of the connective tissue of the gums, therefore works Flavonoids combined with ascorbic acid synergistically. Rutoside u. a. out Buckwheat (Fagopyrum species, contain 1-4% rutoside) or from flower buds Japanese plant Sophora japonica (contain approx. 15% rutoside) or are with synthesized.
Viele dieser Verbindungen kommen als Bestandteile in Nahrungsmitteln vor. Sie gelten hinsichtlich ihrer Toxizität und Nebenwirkungen als unbedenklich. Many of these compounds are found in food components. they seem regarding their toxicity and side effects as harmless.
Die Erfindung bezweckt durch eine neue Wirkstoffkombination biologisch hochwirksamer Fluoride und Flavonoide einen verbesserten Schutz vor Karies und Parodontose zu erreichen. Diese Aufgabe wird erfindungsgemäß gelöst durch Kombination der oben beschriebenen Wirkstoffkombination z. B. in der Applikationsform als Kaugummi/Kaudragee/Bonbon oder Zahnpasta/Mundspülung.The aim of the invention is to achieve a biologically highly effective combination of active substances Fluorides and flavonoids provide improved protection against tooth decay and periodontal disease. This object is achieved according to the invention by combining those described above Active ingredient combination z. B. in the application form as chewing gum / chewing gum / candy or Toothpaste / mouthwash.
Erfindungsgemäß bevorzugte Kau-Bonbons/Kaugummis oder Zahnpasten ermöglichen eine langandauernde kontinuierliche Wirkstoffabgabe, die für eine optimale Fluoridwirkung am Zahn unabdingbar ist. Aminfluoride wirken umso besser, je geringer die Wirkstoffkombination dosiert ist und je länger diese auf den Zahnschmelz und in der Mundhöhle wirken kann. Aus diversen Publikationen ist bekannt, daß Aminfluoride reparative Vorgänge am Zahn fördern (Remineralisierung durch Karies geschädigter Zähne im Anfangsstadium mit Hilfe von Aminfluoriden möglich). Synergistisch wirkt hierbei der präventive Effekt der Flavonoide auf die Mikrozirkulation des Zahnfleisches. Da Flavonoide die Ascorbinsäurewirkung synergistisch unterstützt, wird die Behandlung und Ausheilung der Parodontose auch im Hinblick auf das geschädigte Bindegewebsgerüst (fehlende Ausbildung des mesenchymalen Gewebes) des Zahnfleisches gefördert. Aufgrund der hohen Wirksamkeit werden das Rutin (Quercetin-3-rhamnoglukosid), Hesperidin und Naringin in natürlicher oder synthetischer Form (Rutin Derivate wie z. B. Troxerutin und Monoxerutin) bevorzugt. Dieser positive Effekt wird durch die Applikationsform als Kaugummi/Kaudragee/Bonbon oder Zahnpasta aufgrund der langen Wirkdauer erst ermöglicht und kann durch Applikation in einer Retardform noch gesteigert werden.Chewing candies / chewing gums or toothpastes preferred according to the invention enable one Long-lasting continuous release of active ingredients, which ensure an optimal fluoride effect on the Tooth is essential. Amine fluorides work better the lower the Active ingredient combination is dosed and the longer this on the enamel and in the Oral cavity can act. From various publications it is known that amine fluorides Promote reparative processes on the tooth (remineralization of teeth damaged by caries possible in the initial stage with the help of amine fluorides). The works here synergistically preventive effect of the flavonoids on the microcirculation of the gums. Because flavonoids the ascorbic acid effect supports synergistically, the treatment and healing of Periodontosis also with regard to the damaged connective tissue structure (lack of training of the mesenchymal tissue) of the gums. Because of the high effectiveness be the rutin (quercetin-3-rhamnoglucoside), hesperidin and naringin in natural or synthetic form (rutin derivatives such as troxerutin and monoxerutin) preferred. This The application form as chewing gum / chewing gum / candy or Toothpaste is only possible due to the long duration of action and can be applied in in a slow release form.
Darüberhinaus werden durch die antibiotische Wirkung der Amin/Zink-fluoride Erkrankungen der Zähne (z. B. Karies) und des Zahnfleisches (z. B. Parodontose) kausal bekämpft (H. Schmidt, Chemie und Oberflächenwirkungen der Aminfluoride, Dtsch. Zahnärztl. Z. 38, 1983, Sonderheft 1).In addition, due to the antibiotic effect of the amine / zinc fluoride Causal diseases of the teeth (e.g. caries) and gums (e.g. periodontitis) fought (H. Schmidt, chemistry and surface effects of amine fluoride, Dtsch. Dentist Z. 38, 1983, special issue 1).
In Süßwaren aller Art (incl. Zucker/Alkohol-haltige Getränke) bewirken beigemischte Amin/Zink- Fluoride eine Neutralisierung der kariogenen Abbauprodukte von Glucose/Fructose- Verbindungen. Diese schädlichen kariogenen Wirkungen können damit deutlich reduziert oder sogar aufgehoben werden. In confectionery of all kinds (incl. Sugar / alcohol-containing drinks), amine / zinc Fluorides neutralize the cariogenic breakdown products of glucose / fructose Links. These harmful cariogenic effects can thus be significantly reduced or even be canceled.
Aufgrund der Einwirkung der Aminfluoride über ein langgezogenes flaches Profil (ähnlich der Trinkwasserfluoridierung), welches bekanntermaßen kurzfristigen sehr hohen Konzentrationen (Tablettenfluoridierung) vorzuziehen ist, muß eine sehr niedrige Fluoridkonzentration pro Stück Kaugummi/Kaudragee/Bonbon im Interesse optimaler Wirksamkeit angestrebt werden. Die Fluoridmenge pro Einheit sollte unter 0,05 mg liegen. Die Menge an Flavonoiden pro Einheit kann aufgrund der Unschädlichkeit als sehr variabel angesehen werden. 10-50 mg zeigen bereits eine ausreichende Wirkung auf die Mikrozirkulation und unterstützen synergistisch die Ascorbinsäurewirkung. Die Ascorbinsäure (Vitamin C) kann nicht überdosiert werden. Ausreichend sind hier Mengen zwischen 5-50 mg.Due to the action of the amine fluorides over an elongated flat profile (similar drinking water fluoridation), which is known to be short-term very high Concentrations (tablet fluoridation) is preferable, must be very low Fluoride concentration per chewing gum / chewing gum / candy in the interest more optimal Effectiveness should be sought. The amount of fluoride per unit should be less than 0.05 mg. The amount of flavonoids per unit can be very variable due to the harmlessness be considered. 10-50 mg already show a sufficient effect on the Microcirculation and synergistically support the ascorbic acid effect. The Ascorbic acid (vitamin C) cannot be overdosed. Amounts are sufficient here between 5-50 mg.
Zusammensetzung:
Kaumasse: Synthese Kautschuke z. B. Styrol-Butadien, Butyl
Süßstoffe: z. B. Sorbit (E420), Mannit (E421), Xylit (E967)
Antioxidationsmittel: z. B. Butyl
Aminfluorid 0,05 mg
Flavonoide z. B. ein synthetisches Rutosid-Derivat (Troxerutin
oder Monoxerutin 50 mg)
Ascorbinsäure 50 mg
Natürliche oder naturidentische Aromastoffe
FarbstoffeComposition:
Chewing mass: Synthesis of rubbers e.g. B. styrene-butadiene, butyl
Sweeteners: e.g. B. Sorbitol (E420), Mannitol (E421), Xylitol (E967)
Antioxidants: e.g. B. Butyl
Amine fluoride 0.05 mg
Flavonoids e.g. B. a synthetic rutoside derivative (troxerutin or monoxerutin 50 mg)
Ascorbic acid 50 mg
Natural or nature-identical flavorings
Dyes
Zusammensetzung:
Glucosesirup gehärtet
Aminfluorid 0,05 mg
Flavonoide z. B. ein synthetisches Rutosid-Derivat (Troxerutin
oder Monoxerutin 50 mg)
Ascorbinsäure 50 mg
Natürliche oder naturidentische Aromastoffe
FarbstoffeComposition:
Hardened glucose syrup
Amine fluoride 0.05 mg
Flavonoids e.g. B. a synthetic rutoside derivative (troxerutin or monoxerutin 50 mg)
Ascorbic acid 50 mg
Natural or nature-identical flavorings
Dyes
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1999149575 DE19949575A1 (en) | 1999-10-14 | 1999-10-14 | Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1999149575 DE19949575A1 (en) | 1999-10-14 | 1999-10-14 | Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19949575A1 true DE19949575A1 (en) | 2001-04-19 |
Family
ID=7925656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1999149575 Ceased DE19949575A1 (en) | 1999-10-14 | 1999-10-14 | Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19949575A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009699A2 (en) * | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
DE10312173A1 (en) * | 2003-03-19 | 2004-09-30 | Ingo Hornung | Chewing gum is provided with active ingredients intended to produce beneficial effects on the mouth cavity, pharynx, esophagus, stomach and digestive trac |
WO2008009958A1 (en) | 2006-07-20 | 2008-01-24 | Oraldent Limited | Oral compositions, their preparation and use |
FR2915386A1 (en) * | 2007-04-24 | 2008-10-31 | Pierre Fabre Medicament Sa | USE OF AQUEOUS EXTRACT OF GRAPE PEPINS IN ASSOCIATION WITH AT LEAST ONE FLUOR SALT AGAINST THE FORMATION OR ACCUMULATION OF DENTAL BIOFILM AND THE COMPOSITIONS COMPRISING SAID ASSOCIATION |
DE102008014226A1 (en) | 2008-03-16 | 2009-09-17 | MEDERER Süßwarenvertriebs GmbH | Preparing a remineralizing candy additive, useful e.g. as lollipops and pastilles, comprises dissolving an organic calcium salt in hot water, concentrating the solution, adding an organic acid, and concentrating the solution |
RU2500384C1 (en) * | 2012-08-16 | 2013-12-10 | Общество с ограниченной ответственностью Концерн "КАЛИНА" | Mouth rinse formulation |
RU2505283C1 (en) * | 2012-08-16 | 2014-01-27 | Общество с ограниченной ответственностью Концерн "КАЛИНА" | Toothpaste composition |
-
1999
- 1999-10-14 DE DE1999149575 patent/DE19949575A1/en not_active Ceased
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009699A2 (en) * | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
WO2002009699A3 (en) * | 2000-07-28 | 2003-01-03 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
EA008612B1 (en) * | 2000-07-28 | 2007-06-29 | Иммуфарм Апс | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
US8003688B2 (en) | 2000-07-28 | 2011-08-23 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
DE10312173A1 (en) * | 2003-03-19 | 2004-09-30 | Ingo Hornung | Chewing gum is provided with active ingredients intended to produce beneficial effects on the mouth cavity, pharynx, esophagus, stomach and digestive trac |
EP2043593A1 (en) * | 2006-07-20 | 2009-04-08 | OralDent Limited | Oral compositions, their preparation and use |
WO2008009956A1 (en) | 2006-07-20 | 2008-01-24 | Oraldent Limited | Combinations for oral compositions, their preparation and use |
WO2008009958A1 (en) | 2006-07-20 | 2008-01-24 | Oraldent Limited | Oral compositions, their preparation and use |
EP2043593B1 (en) * | 2006-07-20 | 2012-04-04 | OralDent Limited | Oral compositions, their preparation and use |
US9532939B2 (en) | 2006-07-20 | 2017-01-03 | Ricerfarma S.R.L. | Combinations for oral compositions, their preparation and use |
US9987214B2 (en) | 2006-07-20 | 2018-06-05 | Oraldent Limited | Combinations for oral compositions, their preparation and use |
FR2915386A1 (en) * | 2007-04-24 | 2008-10-31 | Pierre Fabre Medicament Sa | USE OF AQUEOUS EXTRACT OF GRAPE PEPINS IN ASSOCIATION WITH AT LEAST ONE FLUOR SALT AGAINST THE FORMATION OR ACCUMULATION OF DENTAL BIOFILM AND THE COMPOSITIONS COMPRISING SAID ASSOCIATION |
WO2008132149A1 (en) * | 2007-04-24 | 2008-11-06 | Pierre Fabre Medicament | Use of an aqueous grape seed extract combined with at least one fluorine salt to combat the formation or accumulation of dental biofilm and compositions comprising said combination |
DE102008014226A1 (en) | 2008-03-16 | 2009-09-17 | MEDERER Süßwarenvertriebs GmbH | Preparing a remineralizing candy additive, useful e.g. as lollipops and pastilles, comprises dissolving an organic calcium salt in hot water, concentrating the solution, adding an organic acid, and concentrating the solution |
RU2500384C1 (en) * | 2012-08-16 | 2013-12-10 | Общество с ограниченной ответственностью Концерн "КАЛИНА" | Mouth rinse formulation |
RU2505283C1 (en) * | 2012-08-16 | 2014-01-27 | Общество с ограниченной ответственностью Концерн "КАЛИНА" | Toothpaste composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI75269B (en) | MUNVATTENKOMPOSITIONER INNEHAOLLANDE HEXETIDIN OCH ZINKSALTER. | |
RU2432150C2 (en) | Improved oral compositions containing zinc citrate and/or tocopherol ingredients | |
DE60212673T2 (en) | COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND TREATMENT OF RELATED DISEASES | |
DE60035344T2 (en) | ANTI-SENSITIVITY DENTAL DIMENSIONS | |
US6503483B2 (en) | Dental formulation | |
US8524198B2 (en) | Xylitol dental maintenance system | |
EP1466003B1 (en) | Herbal composition for improving oral hygiene, and methods of using same | |
US6207137B1 (en) | Dental formulation | |
ES2306801T3 (en) | SOLID ORTIS COMPOSITIONS ANTISARRO AND ANTIPLACA. | |
AU2014232903A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
DE3706142A1 (en) | SOLID ORAL CARE AGAINST TOOTHSTONE AND BODY ODOR | |
EP0510158B1 (en) | Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and metal salts | |
US20170071840A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
PT99379A (en) | PROCESS FOR THE PREPARATION OF APPROPRIATED ANTI-PLATE COMPOSITIONS CONTAINING A MORFOLINO-AMINO GROUP ALCOHOL AND A CHELATING AGENT | |
DE102004052308B4 (en) | Octenidine-containing lozenges against inflammatory diseases of the mouth and throat | |
DE19949575A1 (en) | Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders | |
DE2629884A1 (en) | ORAL AND DENTAL CARE PRODUCTS | |
WO2002076433A1 (en) | Dental formulation | |
RU2308938C2 (en) | Solid oral compositions | |
DE102015218892A1 (en) | Application mixture for increasing the effect of antiseptics and / or disinfectants, application agent with the content of the application mixture and the use of this mixture | |
DE60221989T2 (en) | ORAL PRODUCTS CONTAIN A FLUOR-ION VECTOR AND ANTIOXIDANT | |
DE2606533A1 (en) | Xylitol for treatment of caries and pre-carious conditions - remineralises the tooth substance and reduces carious lesions (BE190876) | |
JPS6296408A (en) | Drug for oral cavity | |
KR20160061852A (en) | Oral composition containing both metal chelating agent and isopropylmethylphenol | |
KR100843845B1 (en) | Composition for enhancing oral health containing xanthorrhizol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8120 | Willingness to grant licenses paragraph 23 | ||
8127 | New person/name/address of the applicant |
Owner name: HINZ, MICHAEL HERMANN, DR.MED., 82131 GAUTING, DE |
|
8110 | Request for examination paragraph 44 | ||
8131 | Rejection |